Articles tagged "HLA antibodies"

2019 American Transplant Congress
Presence of DSA Class 2 is Associated with Fibrosis Progression after OLT
M. Sterneck¹, B. Sultani², M. Rodriguez Lago³, E. Grabhorn⁴, A. Briem-Richter⁴, U. Herden⁵, L. Fischer⁵
¹University Medical Center Hamburg Eppendorf, Hamburg, Germany, ²University Transplant Center, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ³Depatment of Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁴Department of Paediatric Medicine, University Medical Center Hamburg Eppendorf, Hamburg, Germany, ⁵Department of Visceral Transplantation, University Medical Center Hamburg Eppendorf, Hamburg, Germany
*Purpose: For decades, donor-specific antibodies (DSA) have been thought not to be clinically relevant in orthotopic liver transplantation (OLT). However, recent studies have shown a…
2019 American Transplant Congress
Global Analysis of Fc-gamma Receptors Binding Capacity of Human Leukocyte Antigen Donor Specific Antibody
E. S. Woodle, A. Girnita
University of Cincinnati Academic Health Center, Cincinnati, OH
*Purpose: Functional assessment of anti-HLA antibodies has historically been limited to complement-binding assays. However, antibodies are capable of inducing injury by complement-independent mechanisms, including Fc-gamma…
2019 American Transplant Congress
Yellow Fever and Renal Transplantation: Influence of Vaccination and Infection on the Emergence of Antibody-Mediated Rejection
M. V. Sousa¹, R. L. Zollner², R. S. Stucchi³, I. F. Boin⁴, E. C. Ataide⁴, M. Mazzali¹
¹Department of Internal Medicine - Division of Nephrology, University of Campinas, Campinas, Brazil, ²Department of Internal Medicine, University of Campinas, Campinas, Brazil, ³Department of Internal Medicine - Division of Infectious Diseases, University of Campinas, Campinas, Brazil, ⁴Surgery Department, University of Campinas, Campinas, Brazil
*Purpose: Yellow fever (YF) is a viral hemorrhagic disease transmitted by mosquitos, with variable clinical disease manifestations from a mild, undifferentiated febrile illness to severe…
2019 American Transplant Congress
Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment
X. Zhang¹, S. Jordan²
¹HLA and Immunogenetics Laboratory, Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA, ²Comprehensive Transplant Center, Cedars-Sinai Health System, Los Angeles, CA
*Purpose: Immunoglobulin-degrading enzyme from Streptococcus pyogenes (IdeS, Imlifidase) has been used to reduce antibody levels to promote transplant of highly sensitized patients. In vitro experiments…
2019 American Transplant Congress
MELD Score and Anti-Angiotensin Receptor Antibody Predict Long-Term Survival of Liver Re-Transplant
Q. Xu¹, A. Skaro², V. C. McAlister²
¹Pathology and Lab Medicine, London Health Science Center, London, ON, Canada, ²Surgery, London Health Science Center, London, ON, Canada
*Purpose: Recent reports indicated important while inconsistent roles of preformed donor specific antibody (DSA) to HLA in liver transplantation. Re-transplant liver patients were understudied due…
2019 American Transplant Congress
5-Year Post-Transplant Outcomes with Bortezomib-Based Desensitization in Renal Transplant Recipients
K. Zheng¹, S. Tremblay¹, A. R. Shields², M. A. Cardi², J. Kremer², R. R. Alloway¹, E. S. Woodle¹
¹U of Cincinnati, Cincinnati, OH, ²Christ Hospital, Cincinnati, OH
*Purpose: Renal transplant (RT) after desensitization (DS) has been associated with increased rejection rates. Proteasome inhibitor(PI)-based DS yields significant reductions in HLA Ab among sensitized…
2019 American Transplant Congress
Association between CD19-Positive Rate and Antibody-Mediated Rejection Following Rituximab Administration in Kidney Transplant Recipients
K. Nanmoku, T. Shinzato, T. Kubo, T. Shimizu, T. Yagisawa
Surgical Branch, Institute of Kidney Diseases, Jichi Medical University Hospital, Shimotsuke, Japan
*Purpose: Rituximab, which suppresses antibody production, is widely used for desensitization in ABO-incompatible and donor-specific antibody-positive kidney transplantation. However, data regarding the effects of individual…
2019 American Transplant Congress
IgG4 Subclass Class 2 Donor Specific Antibody (DSA) is Associated with Subclinical Rejection in Stable Pediatric Liver Transplant (LT) Recipients with Normal Liver Tests
A. Jackson¹, S. Kanaparthi², B. Burrell³, D. Lucas⁴, R. Vega⁴, A. J. Demetris⁵, S. Feng⁶
¹Surgery, Duke University, Durham, NC, ²The Immune Tolerance Network, Bethesda, MD, ³Immune Tolerance Network, Bethesda, MD, ⁴Medicine, Johns Hopkins University, Baltimore, MD, ⁵Pathology, University of Pittsburgh, Pittsburgh, PA, ⁶Surgery, University of California San Francisco, San Francisco, CA
*Purpose: DSA is a known biomarker of allograft rejection, yet injury phenotype and potential differ across organs. Among pediatric LT recipients entering iWITH (NCT01638559), an…
2019 American Transplant Congress
The Clinical & Economic Impact Of Allosensitization In Liver Alone And Simultaneous Liver Kidney Transplantation
M. Askar¹, G. Saracino¹, A. Elsabbagh², J. Fung³, T. Srinivas⁴, S. Flechner⁵, J. Trotter¹, G. Testa¹, B. Kaplan⁶, G. Klintmalm¹, J. Schold⁵, S. Asrani¹
¹Transplant Center, Baylor Scott & White, Dallas, TX, ²St. Vincent Health, Indianapolis, IN, ³University of Chicago Medicine, Chigao, IL, ⁴Intermountain Healthcare, Salt Lake City, UT, ⁵Cleveland Clinic, Cleveland, OH, ⁶Transplant Center, Baylor Scott & White, Temple, TX
*Purpose: Allosensitization is thought to have marginal impact among patients that undergo liver transplantation (LTA); further among simultaneous liver kidney transplantation (SLKT), livers may protect…
2019 American Transplant Congress
Reduction of Pre-Existing Alloantibodies in Highly Sensitized Belatacept-Treated Kidney Recipients
R. F. Parsons¹, S. Bumb², H. Decker¹, A. Zahid¹, C. Sullivan¹, T. Pearson¹, C. Larsen¹, M. Levine³, M. Kamoun³, R. A. Bray¹, H. M. Gebel¹
¹Emory University School of Medicine, Atlanta, GA, ²University of Cincinnati, Cincinnati, OH, ³University of Pennsylvania, Philadelphia, PA
*Purpose: Recent evidence suggests that belatacept reduces the durability of pre-existing antibodies to class I and class II human leukocyte antigens (HLA). Belatacept has a…